Mylan Claims Ranbaxy Sitting On Hypertension Drug Exclusivity

Law360, Washington (December 7, 2012, 7:30 PM EST) -- Mylan Pharmaceuticals Inc. told a Washington federal judge on Friday that it should be allowed to start marketing a generic version of its hypertension drug valsartan, alleging Ranbaxy Laboratories Ltd. has forfeited its exclusivity rights by not actively pursuing U.S. Food and Drug Administration approval.

Mylan claims Ranbaxy has had years to seek approval for its abbreviated new drug application yet there's no word when it will be ready to gain final FDA approval for the product, and urged U.S. District Judge John D. Bates to...
To view the full article, register now.